Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

M. Ruella, S. S. Kenderian, O. Shestova, M. Klichinsky, J. J. Melenhorst, M. A. Wasik, S. F. Lacey, C. H. June, S. Gill

Research output: Contribution to journalLetter

32 Scopus citations
Original languageEnglish (US)
Pages (from-to)246-248
Number of pages3
JournalLeukemia
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ruella, M., Kenderian, S. S., Shestova, O., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. (2017). Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia, 31(1), 246-248. https://doi.org/10.1038/leu.2016.262